Following a decision in its first quarter to withdraw from supply
of non-branded phytosterol, Forbes Medi-Tech has revealed a
projected revenue cut of up to two-thirds for 2006, but has
nonetheless posted modest year-to-date profits.
Forbes Medi-Tech has completed the sale of its 50 percent share in
Phyto-Source, its sterol manufacturing joint venture with Chusei
(USA) to Chusei Oil Co for US$25 million, and plans to use the
proceeds to develop more nutraceutical...
After months of negotiations, Canadian nutraceutical products maker
Forbes Medi-Tech has finally reached an agreement with Swiss group
Novartis Consumer Health over the future of the Reducol
Strong phytosterol sales in the first quarter for Canadian company
Forbes Medi-Tech doubles first quarter revenues from last year. The
company reported revenue of C$2.4 billion (€1.6bn), up from C$1.2
billion in the comparable period...
Forbes Medi-Tech remains bullish about its prospects for the future
despite the failure of the Novartis-Quaker Oats joint venture which
was meant to promote a range of foods containing Reducol, the
cholesterol-cutting ingredient developed...
Canadian group Forbes Medi-Tech, a producer of cholesterol-lowering
food ingredients, has been approached by Novartis Consumer Health
to help it find a buyer for the Take Heart line of food products
enriched with Forbes' Reducol.
Health science company Forbes Medi-Tech Inc. announced this week
that it has reached an agreement with Novartis Consumer Health SA
to acquire the licensing and distribution rights to consumer
products fortified with Reducol, the company's...